My current work focuses on developing computational tools to improve prognostic and predictive models in sarcoma with the aim of facilitating more personalized cancer treatments. In particular, I’m interested in integrating results from sophisticated tests on patient tumors -- including next-generation sequencing, proteomics, and metabolimics -- with clinical databases in order to help understand what treatments work best in individual patients. As part of this work, I have led the creation of a Sarcoma Registry at the OSUCCC – James to allow us to capture this clinical data in a rigorous manner.
I’m inspired by the mission of the OSUCCC – James to achieve a cancer-free world, and feel honored to be a part of that vision. Because each patient is unique, the medical and therapeutic regimens we provide should mirror that, and I believe the better our ability to accurately predict responses and customize treatments, the more positive outcomes we will see.
I’ve authored or co-authored 11 medical manuscripts, delivered five presentations and have served as the principal investigator or co-investigator on over 20 clinical studies. I’m excited about the work we’re doing at the OSUCCC – James, and all the potential medical breakthroughs to come.
State University of New York at Buffalo
SUNY at Buffalo
7/1/2008 - 6/30/2010
Specialties and conditions I treat
- Medical Oncology
- Skin Cancers
- Histiocytoma, Malignant Fibrous
- Sarcoma, Synovial
- Sarcoma, Ewing
- Sarcoma, Kaposi
Locations where I practice
More about my work
Ohio State University Wexner Medical Ctr
7/1/2010 - 6/30/2012
American Board of Internal Medicine
American Board of Internal Medicine (Subspecialty: Medicine Oncology)
News about me
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/25/2016, Dr. Liebner has reported no financial relationships with medical device, research and/or drug companies.